EFMC-ISMC 2008
Please download here the attached Excel file with the complete programme.
Final programme schedule with details (21/08/2008 - 67 KB)
Plenary Lectures
STRATEGIES FOR THE DISCOVERY OF INNOVATIVE THERAPEUTICS
Prof Magid ABOU-GHARBIA
(TEMPLE UNIVERSITY, Philadelphia, United States)
Life on the Edge: The Nature and Origins of Protein Misfolding Diseases
Prof. Chris DOBSON
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)
Drug Discovery for Neglected Diseases
Prof. Paul HERRLING
(NOVARTIS INTERNATIONAL, Basel, Switzerland)
Chemical Tools for the Study of Complex Biological Systems
Prof. Barbara IMPERIALI
(MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, United States)
Award Lectures
The Nauta Award for Pharmacochemistry (EFMC)
Changing Paradigms in Drug Discovery
Prof. Hugo KUBINYI
(UNIVERSITY OF HEIDELBERG, Weisenheim am Sand, Germany)
The UCB-Ehrlich Award for Excellence in Medicinal Chemistry (EFMC)
Automated Oligosaccharide Synthesis as Platform for Vaccine Development
Prof. Dr Peter H. SEEBERGER
(MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Berlin, Germany)
GlaxoSmithKline Award forOutstanding Achievement in the Field of Chemical Biology
Exploring Chemical Space with Aptamers
Dr. Michael FAMULOK
(UNIVERSITY OF BONN, Bonn, Germany)
The Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery (EFMC)
New Tools for Molecule Makers: Emerging Technologies
Prof. Steven V. LEY
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)
1. Novel Lead Finding Approaches2. Chemistry Strategies to Reduce Attrition in Drug Discovery3. Emerging Drugs
Session Chair
Prof. Hans Ulrich STILZ
(SANOFI-AVENTIS, Malov, Denmark)
Integration of Fragment Derived Structure-Based Design into the Discovery and Development of Selective Kinase Inhibitors for Treatment of Human Cancers
Dr. Gavin HIRST
(SGX PHARMACEUTICALS, San Diego, United States)
Fragment Based Lead Discovery
Prof. Roderick E. HUBBARD
(UNIVERSITY OF YORK / VERNALIS, York, United Kingdom)
Search for Taxoid Mimics Using Dynamic Combinatorial Chemistry Targeting Tubulin
Ms Claire LE MANACH
(ICMMO, Orsay, France)
Session Chair
Dr Geoffrey STEMP
(GLAXOSMITHKLINE, Harlow, United Kingdom)
From Fragment to Clinic
Dr David REES
(ASTEX THERAPEUTICS, Cambridge, United Kingdom)
Chemical Strategies for Successful Clinical Development
Dr. Christopher N. JOHNSON
(GLAXOSMITHKLINE, Harlow, United Kingdom)
Recent Strategies Around Predicting Oral Absorption
Dr DAVID MILLAN
(PFIZER, Sandwich, United Kingdom)
Session Chair
Dr Bernd RIEDL
(BAYER PHARMA, Wuppertal, Germany)
The Discovery and Development of Rivaroxaban
Dr. Susanne ROEHRIG
(BAYER SCHERING PHARMA, Wuppertal, Germany)
Identification and development of PI3K inhibitors - Path to the clinic
Dr. Carlos GARCIA-ECHEVERRIA
(NOVARTIS PHARMA, Basel, Switzerland)
Discovery of TMC278: a Next Generation NNRTI Drug, Highly Active against Human Immunodeficiency Virus Type-1
Dr Jérôme GUILLEMONT
(JANSSEN-CILAG, Val de Reuil, France)
4. Kinase Selectivity-Is it Necessary? (ACS)5. Predictive ADME/Tox Methods: What to Apply When?6. Macromolecular and Polymeric Drugs
Session Chair
Prof. David ROTELLA
(WYETH, MONTCLAIR, United States)
Kinase Selectivity in Drug Discovery - the Challenges and Opportunities
Dr. Dennis POWELL
(WYETH RESEARCH, Pearl River, United States)
Development of Dibenzosuberones as Potent and Highly Selective p38 MAPK Inhibitors
Prof. Stefan LAUFER
(UNIVERSITY OF TÜBINGEN, Tübingen, Germany)
CDK Inhibition - Selectivity Issues in Principle and in Practice
Dr. Andrew THOMAS
(ASTRAZENECA R&D, Macclesfield, United Kingdom)
Session Chair
Dr Scott BOYER
(ASTRAZENECA, Södertälje, Sweden)
Predictive ADME: Examples from the Real World
Dr. Andrew Mark DAVIS
(ASTRAZENECA R&D, Loughborough, United Kingdom)
Virtual Methods for Predicting Off-Target Pharmacology
Prof. Jordi MESTRES
(IMIM AND UNIVERSITY POMPEU FABRA, Barcelona, Spain)
Predicting Brain to Blood Drug Partitioning: Progress and Limitations
Prof. Gabriele CRUCIANI
(UNIVERSITY OF PERUGIA, Perugia, Italy)
Session Chair
Prof. Abraham J. DOMB
(HEBREW UNIVERSITY OF JERUSALEM, Jerusalem, Israel)
PEG Conjugation in Drug Development and Discovery
Prof. Francesco M. VERONESE
(UNIVERSITY OF PADOVA, Padova, Italy)
Multivalency of Polymer Therapeutics Used for the Integration of Anti-angiogenic Therapy with Chemotherapy
Dr. Ronit SATCHI-FAIRANO
(TEL AVIV UNIVERSITY, Tel Aviv, Israel)
5’-Phosphate Mimics within Altritol-Modified siRNAs and Inhibition of MDR1 Expression
Dr Arthur VAN AERSCHOT
(KULEUVEN, LEUVEN, Belgium)
7. Fragment-Based Drug Discovery (ACS) 8. Imaging Ligands and Biomarkers (EUFEPS)9. Natural Products as Starting Points in Drug Discovery
Session Chair
Dr. Jeffrey ALBERT
(ASTRAZENECA, Wilmington, United States)
EVOlution: Design and Implementation of a Fragment Discovery Platform
Dr. John BARKER
(EVOTEC, OXON, United Kingdom)
Fragment-Based Discovery: What Has it Achieved so far?
Dr. Alexander ALEX
(PFIZER, Sandwich, United Kingdom)
Fragment-Based Methods and the Discovery of BACE-1 Inhibitors for Alzheimer's
Dr. Jeffrey ALBERT
(ASTRAZENECA, Wilmington, United States)
Session Chair
Prof. Pia VUORELA
(ÅBO AKADEMI UNIVERSITY, Turku, Finland)
Fluorometry and FRET in Measuring Biomarkers and Monitoring Cell Signaling Cascade
Dr. Ilkka HEMMILA
(PERKINELMER LIFE SCIENCES, Turku, Finland)
Mass Sensitive Ligands Useful for Biomarker Discovery and Validation
Dr. Rainer VOEGELI
(PROTEOME SCIENCES, Cobham, United Kingdom)
Design of Spin-Labeled Sulfonamides as Carbonic Anhydrase Inhibitors
Dr Alessandro CECCHI
(UNIVERSITY OF FLORENCE, Sesto Fiorentino, Italy)
Session Chair
Dr. Erden BANOGLU
(GAZI UNIVERSITY, Ankara, Turkey)
Biodiverse Natural Products in Drug Discovery
Prof. Douglas KINGHORN
(OHIO STATE UNIVERSITY, Columbus, United States)
How to Use The Structural Diversity of Natural Products for Drug Discovery
Dr. Philipp KRASTEL
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Selectivity in the Antibacterial Activity of Minor Groove Binders, Derivatives of the Natural Product, Distamycin
Prof Colin SUCKLING
(UNIVERSITY OF STRATHCLYDE, Glasgow, Scotland, United Kingdom)
10. Neurodegenerative Diseases11. Type 2 Diabetes12. Progress in COPD and Asthma Therapy
Session Chair
Prof Magid ABOU-GHARBIA
(TEMPLE UNIVERSITY, Philadelphia, United States)
Protein Misfolding and Self-assembly in Neurodegenerative Diseases: From Mechanistic Studies to Therapeutic Strategies
Prof. Hilal A. LASHUEL
(EPFL, Lausanne, Switzerland)
Approaches to the Treatment of Cognitive Dysfunction and Alzheimer’s Disease
Dr Al ROBICHAUD
(SAGE, Princeton, United States)
Halomethylketones (Hmks): Gsk-3 Inhibitors with Disease-Modifying Properties for Alzheimer´S Disease Therapy
Prof. Ana MARTINEZ
(INSTITUTO DE QUIMICA MEDICA-CSIC, Madrid, Spain)
Session Chair
Prof. Koen AUGUSTYNS
(UNIVERSITY OF ANTWERP, Antwerp, Belgium)
DPP-4 Inhibitors: Galvus® / Vildagliptin and Following Generations
Dr. Daniel BAESCHLIN
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Peptidic and Nonpeptidic Glucagon-Like Peptide 1 Receptor Agonists
Dr Jesper LAU
(NOVO NORDISK, Maaloev, Denmark)
Irreversible Inhibition of DPP 8/9 by Dipeptide derived Diaryl Phosphonates
Dr Pieter VAN DER VEKEN
(UNIVERSITY OF ANTWERP, Antwerpen, Belgium)
Session Chair
Dr. Matthias GRAUERT
(BOEHRINGER INGELHEIM, Biberach, Germany)
Recent Developments in CCR3 Antagonists
Dr. George V. DE LUCCA
(BRISTOL-MYERS SQUIBB, Princeton, United States)
PI3Kgamma Inhibitors: Aspirin of the 21st Century?
Dr. Thomas RÜCKLE
(MERCK SERONO, Geneva, Switzerland)
4-Oxo-Beta-Lactams (Azetidine-2,4-diones) Based Novel Potent Inhibitors of Elastase
Dr JALMIRA MULCHANDE
(LISBON UNIVERSTY, Lisbon, Portugal)
13. Allosteric Modulation and GPCR Drug Discovery14. Oncology15. Immunology & Immunomodulation
Session Chair
Prof. Rob LEURS
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)
The Potential of Allosteric Modulation for GPCR Drug Discovery
Prof. Arthur CHRISTOPOULOS
(MONASH UNIVERSITY, Parkville, Australia)
Therapeutic Opportunities for Small Molecule Modulators of Chemokine Receptors
Dr. Thomas J. SCHALL
(CHEMOCENTRYX, Mountain View, United States)
High-Throughput Screening of Potential Drug Candidates For Gpr-17 Receptor by Fac-Ms: Development and Application of a New Gpr17 Stationary Phase
Prof. Gabriella MASSOLINI
(UNIVERSITY OF PAVIA, Pavia, Italy)
Session Chair
Dr Jeremy DAVIS
(UCB, Slough, United Kingdom)
Eg5 Inhibitors
Dr Paul COLEMAN
(MERCK RESEARCH LABORATORIES, West Point, United States)
Allosteric Akt Inhibitors
Dr. George HARTMANN
(MERCK RESEARCH LABORATORIES, West-Point, United States)
PLK1 Inhibitor (BI-2536)
Dr. Matthias HOFFMANN
(BOEHRINGER INGELHEIM, Biberach, Germany)
Session Chair
Dr. Katerina LEFTHERIS
(VITAE PHARMACEUTICALS, Fort Washington, United States)
Current Aspects and Future Trends in Immunomodulation
Dr. Qihong ZHAO
(BRISTOL-MYERS SQUIBB, Princeton, United States)
Advances in Targeting Glucocorticoids
Dr. Markus BERGER
(BAYER SCHERING PHARMA, Berlin, Germany)
Target Validation and Lead Identification of Selective Cb2 Receptor Agonists for the Treatment of Inflammation and Pain
Dr Doris RIETHER
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany)
16. Antispsychotic Targets17. Antivirals18. Pain
Session Chair
Prof Klaus P BOGESO
(H. LUNDBECK A/S, Valby, Denmark)
NK3 Receptors
Dr Klaus Baek SIMONSEN
(LUNDBECK, Valby, Denmark)
PDE10 Inhibitors
Dr. Spiros LIRAS
(PFIZER GLOBAL RESEARCH, Groton, United States)
Dopamine System Stabilizers
Prof. György DOMANY
(GEDEON RICHTER PLC, Budapest, Hungary)
Session Chair
Dr Maria Jose CAMARASA
(CSIC, Madrid, Spain)
Targetting the Glycans on the Viral Envelope, A Novel Therapeutic Concept
Dr. Jan BALZARINI
(REGA INSTITUTE FOR MEDICAL RESEARCH, Leuven, Belgium)
Lethal Mutagenesis as a New Antiviral Strategy
Prof. Esteban DOMINGO
(UNIVERSIDAD AUTONOMA DE MADRID, Madrid, Spain)
’New Developments in NNRTIs of HIV; from TIBO to Rilpivirine
Dr. JAN HEERES
(, Vosselaar, Belgium) - Richter Prize 2008
Session Chair
Dr Erin DIMAURO
(AMGEN, Cambridge, United States)
Emerging Treatments for Chronic Pain: Prospects and Challenges.
Dr. Stefan MCDONOUGH
(AMGEN, Cambridge, United States)
Discovery of a Selective TRPV1 Antagonist, AMG 517: A Clinical Candidate for the Treatment of Pain
Mr Mark NORMAN
(AMGEN, Thousand Oaks, United States)
Novel alpha2delta Ligands for the Treatment of Neuropathic Pain
Dr. Graham N. MAW
(PFIZER, Sandwich, United Kingdom)
19. Exploring the Chemical Space20. Chemokines21. Systems Level Research Informs Drug Target Identification and Therapy Design
Session Chair
Profs. Herbert WALDMANN & STEFAN WETZEL
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)
Computer-Assisted Molecular Design: Voyages to the (un)known
Prof. Gisbert SCHNEIDER
(JOHANN WOLFGANG GOETHE UNIVERSITY, Zürich, Switzerland)
The Quest for Bioisosterism in the “Other Side” of Chemical Space
Dr. Antonio MACCHIARULO
(UNIVERSITY OF PERUGIA, Perugia, Italy)
Exploration of Chemical Space for Drug Discovery by Database Generation
Prof. Jean-Louis REYMOND
(UNIVERSITY OF BERN, Bern, Switzerland)
Scaffold Hunter: Charting and Exploring Chemical Space
Dr. Stefan WETZEL
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)
Session Chair
Prof. Gerhard ECKER
(UNIVERSITY OF VIENNA, Vienna, Austria)
CXCR4 Antagonists: Relevance to Cancer Chemotherapy
Prof. Nobutaka FUJII
(KYOTO UNIVERSITY, Kyoto, Japan)
Selective Dual CCR2/5 Antagonists
Dr. Wolfgang MILTZ
(NOVARTIS PHARMA, Basel, Switzerland)
Biological Profiling of Anti-HIV Agents using in Silico Techniques: Insights into CCR5 Ligands Binding Through Homology Buildings, 3D-QSAR, Docking and Shape Matching Virtual Screening
Mr Antonio CARRIERI
(DDIPARTIMENTO FARMACO-CHIMICO, Bari, Italy)
Session Chair
Prof. Harel WEINSTEIN
(CORNELL UNIVERSITY, New York, United States)
Drug Discovery, Drug Delivery and Therapeutic Monitoring by Molecular, Cellular and Functional Imaging of Atherothrombosis
Dr. Zahi A. FAYAD
(MOUNT SINAI SCHOOL OF MEDICINE, New York, United States)
Understanding Drug Mechanisms and Designing Therapy at the Systems Level of the Functional Human Interactome
Prof. Gianni CESARENI
(UNIVERSITY OF ROME 'TOR VERGATA', Rome, Italy)
Special Structural, Dynamic and Functional Characteristics of Membrane Proteins and their Signaling Partners that Determine the Mode and Putative Success of Therapy Design Targeting Cellular Signaling Systems.
Prof. Harel WEINSTEIN
(CORNELL UNIVERSITY, New York, United States)
22. New Computational Approaches Supporting Drug Design23. Druggability of Protein-Protein Interactions24. Systems Biology and Medicinal Chemistry
Session Chair
Prof. Jordi MESTRES
(IMIM AND UNIVERSITY POMPEU FABRA, Barcelona, Spain)
Overview on New Computational Tools Supporting Drug Design
Prof. Tudor I. OPREA
(UNIVERSITY OF NEW MEXICO, Albuquerque, United States)
Novel Tools for Data Gathering
Dr. Muthukumarasamy KARTHIKEYAN
(NATIONAL CHEMICAL LABORATORY, Pune, India)
Novel Tools for Data Classification
Dr. Ansgar SCHUFFENHAUER
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Novel Tools for Data Exploitation
Dr. Elisabet GREGORI-PUIGJANE
(CHEMOTARGETS, Barcelona, Spain)
Session Chair
Mr Peter NUSSBAUMER
(LEAD DISCOVERY CENTER, DORTMUND, Germany)
Mapping the Binding Cite of Substrate Targeting Gamma-secretase Modulators. Phase III Candidates for Alzheimer´s Disease Utilize a Novel Protein-protein Interaction
Prof. Boris SCHMIDT
(TU DARMSTADT, Darmstadt, Germany)
Rational Design of Cytotoxic Peptides from the Analysis of Protein-Protein Interactions in Microtubules
Dr pieraccini STEFANO
(UNIVERSITY OF MILANO, Milano, Italy)
Peptidomimetic Inhibitors of the PSD-95/NMDA Receptor Interaction
Mr Anders BACH
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)
Dynamic Ligation Screening: A Method for the Site-Directed Discovery of Inhibitory Fragments
Prof Jörg RADEMANN
(UNIVERSTITÄT LEIPZIG, Leipzig, Germany)
Session Chair
Prof Christian NOE
(UNIVERSITY OF VIENNA, Vienna, Austria)
Network Based Drug Discovery
Prof. Hans WESTERHOFF
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)
Systems Biology – What Does it Mean for Pharmaceutical Science?
Prof Christian NOE
(UNIVERSITY OF VIENNA, Vienna, Austria)
Integrated Approach for the Multireceptorial Design of Antipsychotic Agents
Dr Jana SELENT
(HOSPITAL DEL MAR MEDICAL RESEARCH INSTITUTE (IMIM), Barcelona, Spain)
25. Structure Based Drug Design (AFMC)26. Modulators of Adenosine and P2Y Receptors27. Addressing Therapeutic Complexity in Oncology with Med. Chem.
Session Chair
Prof. Esin AKI-SENER
(ANKARA UNIVERSITY, Ankara, Turkey)
Quantum Chemical Calculation of Protein-Ligand Interaction
Prof. Isao NAKANISHI
(KINDAI UNIVERSITY, Higashi-osaka, Japan)
Inhibiting ROS Toxicity in Alzheimer's Disease: Structural Studies of Amyloid-Beta and Metal Ion Complexes
Dr. Jose VARGHESE
(CSIRO, Parkville, Australia)
Access and Binding of Local Anesthetics in the Closed Sodium Channel
Ms Iva BRUHOVA
(MCMASTER UNIVERSITY, Hamilton, Canada)
Session Chair
Prof. Kenneth A. JACOBSON
(NIDDK, Bethesda, United States)
Engineering of Purine Receptors and Their Ligands
Prof. Kenneth A. JACOBSON
(NIDDK, Bethesda, United States)
New modulators of A3 and A2B adenosine receptors
Prof. Pier Giovanni BARALDI
(UNIVERSITY OF FERRARA, Ferrara, Italy)
Allosteric Modulation of Purine Receptors
Prof. Ad P. IJZERMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)
Session Chair
Dr Janet ROBERTSON
(TES PHARMA S.R.L., Corciano , Italy)
Alternatives to Kinase Inhibitors for Cancer Therapies
Prof. Giovanni GAVIRAGHI
(SIENA BIOTECH, Siena, Italy)
Endothelin Converting Enzyme Inhibitors as Anticancer Agents for Human Glioblastoma. A Comparison with Endothelin Receptor Antagonists
Dr. Lucienne JUILLERAT
(CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS, Lausanne, Switzerland)
Structure-Activity Relationships and Cancer-Selective Toxicity of Novel Inhibitors of Gli1 Transcription
Dr Naoaki FUJII
(ST. JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, United States)
FORUM DISCUSSION
A.Golinowska3 LINK TO FORUM DISCUSSION PARTICIPANTS
How to close the gap between academic training in medicinal chemistry and industrial reality?
Moderator
Prof. Péter MÁTYUS
(SEMMELWEIS UNIVERSITY, Budapest, Hungary)
WORKSHOPS
ACCELRYS NIKEM LINK TO WORKSHOPS DESCRIPTION
ACCELRYS
A.Golinowska COOL TOOLS FROM ACCELRYS: HELPING TO AUTOMATE MEDICINAL CHEMISTRY EVERYDAY TASKS
(BIOVIA, Belgium)
NIKEM RESEARCH
A.Golinowska2 FROM IDEAS TO PRECLINICAL CANDIDATES: MEDCHEM-DRIVEN DRUG DISCOVERY AT NIKEM
<Previous page


Organized by

On behalf of

PREMIER SPONSORS

CORPORATE SPONSORS

WORKSHOP SPONSORS

CONTRIBUTORS

AWARDS SPONSORS

EFMC TRAVEL GRANTS SPONSOR

BEST POSTER AWARDS SPONSOR

MEDIA PARTNERS